Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial

Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial

Abstract Background The close interplay between metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes supports the need to identify beneficial combination therapies of antidiabetic medications targeted for the treatment of MASLD. This study aimed to investigate the com...

Full description

Saved in:
Bibliographic Details
Main Authors: Minyoung Lee, Sukchul Hong, Yongin Cho, Hyungjin Rhee, Min Heui Yu, Jaehyun Bae, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Medicine
Subjects:
Metabolic dysfunction-associated steatotic liver disease
Type 2 diabetes
Thiazolidinedione
Sodium-glucose cotransporter 2 inhibitor
Online Access:https://doi.org/10.1186/s12916-025-04017-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12916-025-04017-x

Similar Items